Clinical Trials

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00452023 2024-12-11

Pegasys® in Patients With Myeloproliferative Diseases

83 enrolled 12 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential

NCT04798612 2023-08-18

IPOS

Phase 2 Unknown

68 enrolled

Colonic Neoplasms

NCT05729139 2023-08-09

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Phase 1 Withdrawn

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

8 enrolled 11 charts

Dermatologic

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

NCT01387763 2022-04-27

DALIAH

202 enrolled

Other hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT02328755 2021-10-06

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Phase 1/2 Completed

37 enrolled 20 charts

Leukemia, Myeloid, Acute

NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Phase 3 Terminated

1 enrolled 3 charts

Hepatitis C, Carcinoma, Hepatocellular, Infections

NCT02381379 2020-09-14

MSIT

Phase 3 Unknown

118 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

158 enrolled

Solid Cancers

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Phase 1 Completed

13 enrolled

Polycythemia Vera, Thrombocythemia, Essential

NCT01259856 2019-04-30

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

168 enrolled 16 charts

Polycythemia Vera, Thrombocythemia, Essential

NCT03253250 2017-09-08

The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection

Phase 4 Unknown

432 enrolled

Carcinoma, Hepatocellular, Hepatitis B, Chronic

NCT00204529 2017-05-03

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

901 enrolled

Dermatologic

Melanoma

NCT01259817 2017-01-11

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

135 enrolled

DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2/3 Completed

9 enrolled 7 charts

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02576964 2016-11-02

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

16 enrolled

Carcinoma, Hepatocellular

NCT02736721 2016-09-20

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

41 enrolled 8 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00241241 2015-10-21

Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera

40 enrolled

Myeloproliferative Disorders, Polycythemia Vera

NCT00630084 2015-09-04

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

Phase 4 Completed

120 enrolled

Neoplasms, Hepatitis C, Chronic

NCT01392170 2015-05-04

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Phase 2 Terminated

2 enrolled 3 charts

LymphoidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT00423397 2013-12-19

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Unknown

16 enrolled

Dermatologic

Skin Neoplasms

NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Phase 2 Terminated

2 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Phase 1/2 Withdrawn

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00253474 2012-03-29

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

Phase 1 Completed

36 enrolled

Other solid neoplasm

Neoplasm of Uncertain Malignant Potential

NCT00047879 2011-10-26

Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas

7 enrolled 8 charts

CNS

Brain Neoplasms, Glioma

NCT00763763 2011-10-05

AFR07

LymphoidMyeloidOther hematologic neoplasm

55 enrolled

Blast Crisis, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00178763 2011-03-03

FR-WB-TT

Phase 2 Unknown

36 enrolled

Neoplasms, Pancreatic Neoplasms

NCT00834860 2010-02-15

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma

Phase 4 Unknown

179 enrolled